Medications like Ozempic (semaglutide), Wegovy (higher dose of semaglutide), Mounjaro, and Zepbound (tirzepatide) mimic this hormone, sending signals to your brain that increase feelings of fullness and satisfaction
Saxenda is the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults
The OGDC is very similar to the PDH complex in the intricacy of its protein makeup (E1, E2, and E3 activities), cofactors (TPP, lipoic acid, CoA, FAD, and NAD + ), and its mechanism of action
GLP-1 RAs showed trends toward improvements in endocrine and metabolic, cardiovascular, renal, and respiratory outcomes, cognitive function, with a potential reduction in fracture risk and all-cause mortality in certain populations
Study period 1/1/2017 to 7/1/2025 Study population: inclusion Patients with A GLP-1 prescription for at least 90 days At least five pounds of weight loss while on the GLP-1 A weight reading between 30 days prior through 3 days after starting the GLP-1 A weight reading within 30 days of stopping the GLP-1 At least one weight reading 1 to 24 months following end of the GLP-1 Study population: exclusion Thyroid conditions (ever): ICD-10-CM E03*or E05* Eating disorders (ever): ICD-10-CM F50* Pregnancy within a year before GLP-1 start through GLP-1 stop Censoring Other weight loss medication or restart of GLP-1 Amputation Bariatric surgery Pregnancy that started in period after GLP-1 was stopped Outcomes Percent of weight change relative to initial weight loss after end of GLP-1 treatment GLP-1 A medication with a simple generic of semaglutide, liraglutide, or tirzepatide
)
